Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EPS (Weighted Average and Diluted) (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.04 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 60.0% to -$0.04 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.02, a 93.94% increase, with the full-year FY2025 number at -$0.02, up 93.94% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.04 for Q4 2025 at Akebia Therapeutics, down from $0.0 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.16 in Q2 2022 to a low of -$0.52 in Q2 2021.
  • A 5-year average of -$0.14 and a median of -$0.08 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 3153.18% in 2024, then surged 133.33% in 2025.
  • Akebia Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.4 in 2021, then skyrocketed by 90.0% to -$0.04 in 2022, then skyrocketed by 108.19% to $0.0 in 2023, then tumbled by 3153.18% to -$0.1 in 2024, then soared by 60.0% to -$0.04 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's EPS (Weighted Average and Diluted) are -$0.04 (Q4 2025), $0.0 (Q3 2025), and -$0.01 (Q2 2025).